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ABSTRACT 
The American University in Cairo 
Gold Nanoparticles-Based Sensors for Detection of Mycobacterium tuberculosis 
Genomic DNA 
By: Amira Hazem Mohamed Mansour 
Under the supervision of Prof. Dr. Hassan M.E. Azzazy 
 
Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB), is an airborne disease 
that strikes one third of the globe’s population. In addition to infection of 9.6 million 
patients, TB claimed the lives of 1.5 million people in 2014 only. The majority of TB 
patients are present in the third world where the balance between cost-effective 
diagnostic method and prevalence of TB is difficult to achieve. Accurate diagnosis of 
TB is necessary to timely initiation of treatment. The available diagnostic tools are 
slow, while the rapid methods are either inaccurate or relatively unaffordable. So, 
sometimes the diagnosis is presumptive based on the clinical findings and the 
treatment is empiric. The treatment is lengthy and demands the administration of 
multiple antibiotics. However, the emergence of drug resistance threatened the global 
control programs of TB.  
The objective of this work is to develop cheap, fast and accurate detection methods. 
Two gold nanoparticles (AuNPs) based sensors were developed for colorimetric and 
fluorometric detection of MTB. Seventy two anonymous sputum samples were 
cultured then DNA was extracted. MTB H37Ra was the positive control while M. 
smegmatis and 8 non-MTB and negative controls. Characterization of the samples 
was achieved by multiplex PCR using MTB and NTM specific primers. Random 
samples were amplified by 16S-23S ITS primers and sequenced. Drug resistance 
associated mutations of MDR-TB were identified by MAS-PCR. 
The colorimetric assay aim was the detection of amplified MTB DNA by cationic 
AuNPs. The samples were amplified by IS6110 and rpoB primers. Only MTB 
samples yielded amplicons. So the negatively charged dsDNA attracted the positively 
charged AuNPs inducing their aggregation and the color turned blue. While the 
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negative samples did not yield any amplicons and the AuNPs remained dispersed so 
the color was red. The sensitivity and specificity was 100% and the detection limit 
was 5.4 ng/μl of MTB DNA.  
The fluorometric assay exploited the quenching property of 40 nm AuNPs. The 
unamplified DNA was fragmented in the presence of 16s rDNA specific probe tagged 
with the fluorophore CY-3 by sonication and denatured for 3 min at 95 ºC followed 
by annealing at 52ºC for 45 sec. Then AuNPs were added and the fluorescence was 
measured. By FRET, the relative fluorescence was calculated revealing a cut-off 
value of 3. In MTB samples, the CY3-16s rDNA specific probe hybridized with its 
target and became spaced from the AuNPs allowing high fluorescence to be detected. 
Due to the lack of target-probe hybridization in the negative samples, the AuNPs were 
adsorbed on the probe and thus the fluorescence is quenched. Thirteen samples were 
chosen randomly, amplified and sequenced. Sequencing confirmed that 12/13 samples 
were MTB with 100% concordance with the multiplex PCR and FRET. The assay had 
sensitivity and specificity of 98.6% and 90% respectively and concordance of 98% 
with multiplex PCR. The detection limited was calculated to be 10 ng/ul. In 
conclusion, two AuNPs based sensors were developed to allow low cost and rapid 
detection of MTB on low source settings. The assays are rapid, sensitive and can have 
great potential in clinical practice for TB diagnosis.
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Chapter 1: Introduction and literature review 
 
1.1. History of Tuberculosis (TB)  
Egyptian mummies 4000 years old revealed that TB was a common infection in 
ancient Egypt. It was also described by ancestor Assyrians and the Greeks. 
Mycobacterium tuberculosis (MTB) is believed to be a soil-living microorganism and 
developed to infect humans after serial mutations. It is postulated that the spread of 
TB to Europe was caused by the travelling of animals’ merchants. Later in the modern 
history, TB killed quarter of Europe population in one of the most sever pandemics. 
Better medical precautions and then the introduction of the Bacillus Calmette-Guerin 
(BCG) vaccine sharply declined the morbidity and mortality rate [1]. Unfortunately, 
TB infection spread again due the development of drug resistance strains and the 
human immunodeficiency virus (HIV) pandemics especially in Africa where there are 
now high number patients co-infected with HIV and TB [1, 2].  
 
1.2. Tuberculosis (TB)  
According to the 2014 World Health Organization (WHO) tuberculosis report, l.5 
million patients lost their lives to TB, of which one quarter were co-infected with 
HIV. This number exceeded the death rate of HIV alone which was 1.2 million people 
for the same year (figure 1). It is postulated that 9.6 million people carry MTB bacilli 
worldwide of which two thirds were infected in 2014 only (figure 2) [3]. According 
to the WHO reports about the incidence of TB in Egypt, half of the patients are still 
undiagnosed. In 2014, the incidence is 13 patients per 100,000 and the estimated 
number is 11,700 people with 1% MDR-TB and 6% of the patients are children 
(figure 3) [4]. TB is a contagious disease of the respiratory system and may progress 
to be extra pulmonary infection and disseminate to other organs such as the bones, 
lymph nodes, the brain, the spinal cord, the skin, the genital tract and the abdomen. It 
is important to note that not all carriers of MTB have the disease. According to the 
immune response of the host, some of them have active infection as the bacilli can 
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stay dormant for years. Malnutrition, poor aeration and low exposure to sun light and 
immune-comprising condition as co-infection with other disease like HIV are all 
essential factors that can activate the infection [1]. Therefore, TB is more prevalent in 
the developing countries where poverty prevails [5]. Limited resources affect 
accessibility to effective diagnostic methods and treatment. Also, poor medical 
awareness and poverty adversely affect compliance to treatment and thus increase 
incidence of drug resistance [6]. In efforts to control the global TB strike, WHO 
established the STOP TB program which has several missions in order to eradicate 
TB. It prepares road maps for adequate TB diagnosis, treatment and prevention. The 
organization main activities were divided into DOTS (Direct observed therapy, short 
courses) and research to innovate new drugs and vaccines. DOTS program served 32 
million TB patients and contributed to the cure of 28 million people. Their services 
are also beneficial for MDR-TB and HIV patients [7]. The TB Research Movement 
that was developed by Stop TB Partnership and WHO, recommends the development 
of new diagnostic tools characterized by feasibility in limited resource settings, short 
turn-around time, cost-effectiveness, availability at the point of care (POC) level, 
possible differentiation between different TB forms (drug-sensitive, drug-resistant, or 
MDR-TB) and usefulness in pediatric TB patients [8].  
 
1.3. Mycobacterium tuberculosis  
The Mycobacterium genus is composed of Mycobacterium tuberculosis complex 
(MTBC) members, M. Leprae and non-tuberculous mycobacterium (NTM) [9]. 
MTBC has 8 members which are MTB, M. canettii, M. africanum, M. bovis, M. 
caprae, M. microti, M. pinnipedii, and M. Bovis and the attenuated BCG vaccine 
strain. However, only the MTB is the main causative agent of TB and the other 
species rarely cause human infection [10]. The name of genus is originated from term 
Myco- which means fungus due to their morphology which looks like fibers [11]. It is 
cultured on either solid medium as Lowenstein Jensen (LJ) and appears as clusters or 
on liquid culture medium (middlebrook 7H9 broth) where the growth is faster and 
appears as turbidity. Because the staining by carbol fuschin is not dissolved by acid-
alcohol, it is called acid fast [12]. MTB bacilli are intracellular gram positive aerobic 
non-motile bacteria which infects macrophages [13]. The bacilli (0.5 to 3 µm) are 
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well known by their long duplication time that reaches 20 hours [10,14]. The 
morphology of MTB bacilli may vary according to the surrounding media. For 
example, the MTB bacilli tend to be oval in shape in case of nutrient deficiency. 
Inside the macrophages, they look like fibers. Extreme drug resistant-TB (XDR-TB) 
may grow as branched filaments. The cell wall consists of two layers. The outer layer 
is composed of several proteins and lipids while the inner one is characterized by the 
presence of mycolic acids linked to peptidoglycan and arabinogalactan (figure 4). The 
peptidoglycan confers the bacilli its shape [15].  
The genome of the reference strain MTB H37Ra consists of more than 4 million base 
pairs. It is characterized by the presence of about 200 out of 4000 genes for fat 
metabolism only which is considered relatively a high number. This explains the 
ability of MTB bacilli to use the host’s cells as the carbon source. MTB does not have 
defined virulent factors. However, its ability to live inside the macrophages, 
production of certain proteins as katG and SodA which neutralize the toxic secretions 
of the macrophages and the rigid lipid rich cell wall (plays a key role in drug 
resistance) are the main defense mechanisms [1]. 
 
1.4. Pathophysiology of TB 
Inhalation of only one to three bacilli is enough to induce infection. After inhalation 
of MTB bacilli most of the bacilli are exhaled away but some may sneak to the lower 
respiratory tract. The macrophages move to the site of infection and destroy the 
bacilli. In case of the failure of the macrophages to terminate the bacteria, the 
macrophages engulf the bacilli forming a tubercle where the bacteria remain dormant 
then solidifies and appears in chest x-ray. This is called Ghon complex and it is 
characterized by its low pH and oxygen deficiency. All these rigid conditions alter the 
bacilli replication but do not eradicate them. Moreover, they can stay dormant in these 
conditions for years [1, 12]. If the host’s immunity becomes weaker, this granuloma 
may soften and the bacteria spread to the lung and other organs as the lymph nodes 
resulting in active infection [12].The symptoms of the active disease are vague and 
non-specific. They include general fatigue, fever, night sweets and productive cough 
with or without hemorrhage, loss of appetite and therefore unexplained weight loss. 
That is why this disease is sometimes called “consumption” [11]. If the patient is left 
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untreated, MTB causes suffocation of the lungs by two scenarios: severe destruction 
of the lung tissues by decreasing the oxygen supply or granuloma softening which 
releases the bacilli. This process induces internal hemorrhage and tubercle formation 
which also suffocate the patient (figure 5)
 
[1]. Although the rigid cell wall protects 
the bacilli, it is also one of the bacterial virulent factors. The cell wall components of 
the MTB are very distinctive due to the presence of glycolipid lipoarabinomannan 
(LAM) and lipopeptides [1, 11]. The mycolic acids allocated in a vertical position is 
the main bacilli protective shield. Phthiocerol dimycoserate is one of these acids 
which is referred by some authors as the wax ball surrounding the bacteria and its 
virulence is evidenced by its rareness in the attenuated strains [1]. In addition, the cell 
wall morphology is designed to inhibit the host’s enzymatic degradation and 
neutralizes the destructive oxygen and nitrogen derivatives and in the same time, 
other cell wall components induce alveolar macrophages apoptosis. The phagocytosis 
of the MTB bacilli stimulates the secretion of inflammatory cytokines which induces 
bronchial inflammation and aids in granuloma development. Moreover, this process 
recruits the neutrophilis, monocytes and lymphocytes, which accumulate in the site of 
infection and results in bronchoconstriction [11].  
 
1.5. TB Vaccine 
In 1920, the BCG was invented from life attenuated M. bovis and is the only available 
vaccine. However, its efficiency is variant (0-80%) depending on the immune 
response of the vaccinated person. In USA, it is recommended for people at high risk 
only [12]. In Egypt, this vaccine is compulsory for all newborns.  
 
1.6. TB treatment 
The treatment efficiency is affected by two factors; the bacilli may escape to shield 
themselves inside the macrophages so they become unreachable by the antibiotics. 
The second factor is the slow growth which alters the effect of the antibiotics because 
they are active against the bacteria during the growth. Also, drug resistance typically 
develops after prescribing regimens with a single antibiotic [10]. 
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After reliance on streptomycin to treat TB, the British Medical Research council 
reported the first streptomycin resistant cases. It was concluded that multiple 
antibiotics should be administered to cure patients. Because rifampicin and isoniazid 
are the main drugs against TB, strains resistant to both antibiotics are described as 
MDR-TB. In the early 1990s, some countries as USA and Russia had reported high 
number of patients infected with resistant TB. Shortly, these reports were received 
from several other countries [6]. 
TB is defined as MDR-TB when it resists at least rifampicin and isoniazid [16, 17]. 
When the bacteria resist antibiotics from the first line and second line, it is called 
extreme drug resistant TB (XDR-TB) which will lead to patients’ death due to lack of 
treatment [14]. 
The bacterial strain is called resistant when at least 1% of the bacterial population 
resists the antibiotic [18]. Primary resistance is when the patient is infected with a 
resistant strain and secondary which is more common, when the patient is infected 
with susceptible strain but due to inadequate treatment, the bacteria resist the drugs 
[14]. The anti-tuberculous drugs are divided into two categories; first line (table 1) 
and second line antibiotics.   
  
1.6.1. First line antibiotics  
Rifampicin is an essential anti-tuberculous drug which inhibits the transcription of the 
β-subunit of the RNA polymerase. Most of rifampicin resistant strains have mutations 
in the 81-bp region of the rpoB gene which is called Rifampicin Resistance-
Determining Region (RRDR) which are present in codons 507 to 533 [16, 17, 19]. 
The rpoB gene is the encoding gene of the β-subunit of RNA polymerase; a tetra 
subunit enzyme consists of α, β, β’ and δ subunits. In addition, according to the 
mutation site, the resistance degree varies. Mutations in amino acid 526 and 531 result 
in high resistance while in 511, 516, 519 and 522 result in weaker resistance (MIC 
below 64 µg/ml). There is still probability of other mutations in the terminal amino 
acids and need for advanced tests in case of negative result of drug susceptibility test 
[15]. Isoniazid is the second main anti-tuberculous drug which is a prodrug activated 
in the human cell by bacterial catalase peroxidase. The bacteria resist this drug by 
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mutations in the enzyme encoding gene (KatG) to decrease its production. The 
mutations occur mainly in KatG, inhA genes and inhA promoter. Inside KatG only, 
there are several possible mutations and is responsible for 50-90% of isoniazid 
resistant cases. Mutations in other genes are proved to be responsible for isoniazid 
resistance as KasA, aphC and ndh. Resistance to isoniazid is most probably coupled 
with rifampicin resistance [15, 16]. Pyrazinamide is a prodrug used to treat TB 
activated by the enzyme pyrazinamidase in vivo [6, 15]. The bacteria resist it by about 
120 different mutations in pncA gene. By molecular techniques, line probe was able to 
detect all these mutations accurately. However, testing the bacterial susceptibility by 
culture is not easy because the drug is active at acidic pH which inhibits the bacterial 
growth [15]. Ethambutol is activated in vivo and inhibits the attachment of the 
mycolic acids to the cell wall [6]. Resistance to it develops due to mutations in embB 
gene especially in codon 306 which represent 47-62% of the resistance cases. Other 
mutations in codons 330 and 630 result in ethambutol resistance as well. 
Streptomycin is an aminoglycoside antibiotic and is considered as second line in some 
references. Mutations in the genes rrs and rpsL are the common reason to develop 
resistance to streptomycin. However, other mutations in other genes can also cause 
resistance. Till now, there is no rapid method to test the susceptibility of tuberculosis 
to streptomycin [15]. Drug resistance mutation(s) are summarized in (table 2). 
 
1.6.2. Second line antibiotics 
Fluoroquinolones, ethionamide and aminoglycosides as amikacin and kanamycin are 
all active antibiotics against TB [15]. The first line antibiotics are preferred because 
cure can be achieved after 6 months while when administering second line antibiotics, 
the treatment duration will extend to at least 18 months with less efficiency and more 
adverse effects [20].  
 
1.7. TB diagnosis  
Early diagnosis of TB is necessary to eliminate inhalation transmission, prevent 
development of resistance and subsequently reduces death rate from this disease 
especially among HIV co-infected patients [21]. Despite the need for accurate 
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diagnosis of TB, sometimes presumptive diagnosis is done according to the patient’s 
history and confirmed by smear microscopic testing and/or radiological findings [22, 
23]. Also drug susceptibility testing (DST) is not performed until the treatment by the 
first line antibiotics fails or the patient has recurrent TB infection [24]. Timely TB 
diagnosis and drug susceptibility testing using culture-based methods are limited by 
the slow growth of the bacilli. Culturing the bacteria, determine whether it is typical 
or atypical and DST need weeks to perform. Moreover, positive results need rigid 
confirmation [6].  
Further differential testing is now needed due to increase in NTM infections that 
cause similar clinical symptoms to that of MTB. NTMs were considered opportunistic 
infection until the breakthrough of HIV which increased incidence of NTM 
pulmonary infection [25, 26]. The essentiality of differentiation of Mycobacterium 
infections arises from the difference in the drugs regimens used to treat NTM [27]. 
All the diagnostic procedures are summarized in table 3. 
WHO strongly recommends that the governments of the high burden countries should 
participate by a great impact to achieve the goals of END TB program. This program 
is launched by the WHO and has four main activities: early diagnosis of TB and DST 
in addition to regular screening of high risk people, treatment of patients carrying 
drug susceptible and resistant strains, co-operation with HIV programs and finally 
prevention of new infections and vaccines development [24].  
 
1.7.1. Specimens collection and preservation 
Enough sputum should be expectorated by the patients. Some patients as the 
pediatrics and HIV patients have low sputum volume and/or low bacterial load in 
their sputum. Saline spray aids to increase the specimen volume but the patients need 
assistance to use it. The specimen collection and preservation importance arises when 
it is not analyzed on time or needs to travel for further investigation. The lung flute 
(Medical Acoustics, New York, USA), which is FDA approved, helps the patients to 
collect the sputum in-house. It is held by the patient’s mouth and stimulates the lung 
to soften and expectorate the sputum. The second product is produced by Deton Corp. 
(Pasadena, USA) which is a big bag in which the patient coughs. It collects the 
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bacilli-containing droplets and the air is pulled out physically. After specimen 
collection, the second step is the preparation of the sample. OMNIgene SPUTUM 
(DNA Genotek Inc., Ottawa, Canada) produces a liquefaction, decontamination and 
preservation system for the samples without the need for freezing up to 8 days. The 
samples did not have any contamination when investigated on LJ media [24].  
 
1.7.2. Microscopic observation 
The first line diagnostic method for MTB is smear microscopy which is 125 years old 
[12, 28]. It relies on staining of the acid fast bacilli using Ziehl Neelsen (ZN) stain 
(figure 6). It is fast and cheap so used heavily in poor-resources countries for TB 
diagnosis and monitoring the patients receiving anti-tuberculous antibiotics. With 
accuracy varying from 35% to 80%, additional diagnostic method must ascertain the 
negative sample because only one bacillus in the sample is enough to call the sample 
positive. However, 5,000 bacteria/ml are required to be present to allow bacilli 
detection by smear microscopy. Despite the great danger of TB spread from patients 
of high bacterial load, 17% of the misdiagnosed patients by smear microscopy due to 
their low bacterial load transmit the bacilli to their surrounding community [29]. So 
the false negative results are found among HIV patients and extra pulmonary TB 
patients. Also, it does not give information about the bacterial type, its activity and 
drug susceptibility [30]. It is useful to indicate active infection as only viable cell will 
retain the stain while the dead bacilli have leaking cell wall which won’t retain the 
stain. Smear microscopy is recommended for the diagnosis of pulmonary TB with 
minimum of two sputum samples collected in two successive mornings. The 
sensitivity of smear microscopy can be enhanced by concentrating the sputum 
samples. However, this process needs sophisticated biosafety concerns for the 
working technician in addition to the long time consumed [3, 31]. The introduction of 
the fluorescence dyes to stain the MTB bacilli and the use of the fluorescent 
microscopy (FM) enhanced the sensitivity by 10%. Even sample preparation and 
examination extended for shorter time and allowed to increase the number of 
examined samples per day. The spread of the FM in peripheral laboratories was 
altered by the high cost of the bulb and the need for regular maintenance.  The use of 
the potent light emitting diode (LED) allowed the spread of FM after replacing the 
bulb in peripheral laboratories due to its powerful light, lower cost, longer life time of 
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the bulb and elimination of the risk of exposure to mercury vapor in case of bulb 
breakage. WHO recommends the replacement of FM by LED microscopes for smear 
microscopy. The automated microscopy allowed the accurate screening of the 
fluorescent bacilli after manual preparation of the slides. They are accompanied by 
software that analyzes every field in the slide and needs only five minutes for 
complete slide analysis. This microscope dispensed the usage of Xpert MTB/RIF 
(NAAT diagnostic tool recommended by WHO and discussed alter) by 73% for TB 
diagnosis. Becton Dickinson Corp. (New Jersey, USA) also developed an automated 
system that stains the TB smears and analyzes them. its performance is nearly similar 
to LED-microscope [24]. WHO recommends the testing of the smear microscopy by 
the conventional or LED microscopy in the peripheral laboratories [29].   
 
1.7.3. Digital chest X-ray 
Digital chest X-ray allows detection of MTB in resources limited settings 
recommended by the WHO. It is rapid and accurate even in HIV co-infected patients. 
Delft Imaging Systems (Veenendaal, Netherlands) developed the software CAD4TB 
to analyze the images to detect any lung abnormalities (figure 7) [24].   
 
1.7.4. Biomarkers based MTB detection 
 
1.7.4.1. Chromatographic detection of MTB   
Determine™ TB LAM Ag (Alere Inc., Waltham, Massachusetts, USA) is an 
immunochromatographic strip that detects the LAM which is a MTB glycolipid 
present in the living and disseminated bacilli. LAM is detected in the urine and is 
useful for the detection pulmonary and extra pulmonary TB and NTM.  Recent studies 
reported that this assay is a useful indicator for severe infection in HIV patients [24, 
29].   
 
1.7.4.2. Volatile organic compounds (VOC) for detection of MTB 
When TB infection is active, oxidative stress products, volatile compounds and nitric 
oxide are present in the patient’s breath. The detection of these volatile compounds 
offers a non-invasive screening for TB patients [29]. TB Breathalyzer (Rapid 
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Biosesnsor Systems Ltd, UK) is an example device that detects these VOC by just 
coughing in a certain device and the result is available within 4 minutes.  
 
 
1.7.5. Immuno-response based assays 
 
1.7.5.1. Tuberculin test 
It is the injection of low concentration of TB antigen (protein purified derivative) 
subcutaneously. After 48 hours, the injection site becomes red due to immune reaction 
to the antigen (figure 8). The positive result in youth is most probably active 
infection. While in elderly, it may indicate latent infection or vaccination. After this 
test, chest x-ray, microscopic examination of sputum samples, culture and molecular 
diagnosis should be performed. The main drawback is the inability of the test to 
differentiate the active from latent infection and from BCG vaccine [12, 29]. 
1.7.5.2. Serological assays 
 
These assays detect MTB indirectly through capturing the anti-tuberculous antibodies. 
ELISA and LAM-ELISA detect LAM. However, The WHO recommendation is to 
avoid using the blood but use the urine to diagnose TB either pulmonary or extra-
pulmonary. The assay also can’t differentiate between the viable and dead bacilli. The 
sensitivity for pulmonary and extra-pulmonary TB was 65% and 55% respectively. 
Serological test costs about $30 per sample and there is high possibility of false 
negative results [32]. Because the commercial serological tests detect the antibodies, 
they do not differentiate between recent and old infection or even between infection 
and vaccination [29]. TB Interferon-Gamma Release Assays (IGRAs) are other 
example of serological tests that detect the γ-interferon released by the white blood 
cells of the infected people. Due to its poor sensitivity, it does not distinguish between 
active and latent infection. WHO recommends it only in poor resource countries [33].  
 
1.7.6. Bacterial  culture 
 
According to the WHO protocol, smear microscopy and culture are done from sputum 
collected in the early morning from 3 consecutive days. Decontamination of the 
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sputum is a primary step. It is always done by the traditional NAOH-N-acetyl cysteine 
based method. A recent kit called Decomics (Salubris Inc., Massachusetts, USA) 
utilizes beads of high absorption capacity and specific chemicals for proper 
decontamination of sputum [29]. Culture is the second step in the diagnosis and it is 
considered the gold standard method for both MTB detection and DST. Several solid 
culture media are used for isolation, identification, species differentiation and DST as 
Lowenstein-Jensen (LJ), middlebrook 7H10 and blood agar. However, due to the slow 
metabolic activity of MTB, species identification and DST require several weeks to 
obtain conclusive results which extend to 2 and 6 weeks for liquid and solid culture 
medium, respectively [29]. The sensitivity of the culture is 100 bacteria/ml. The 
culture doesn’t allow differentiation of MTB from NTM by initial culture because the 
colonies morphology is nearly identical [29, 34, 35]. The essentiality of species 
differentiation comes from the presence of inherently resistance for specific 
antibiotics. For example; M. bovis, BCG, and M. canettii have innate resistant to 
pyrazinamide [36, 37]. Molecular assays, biochemical tests or additional culture for 2 
to 4 weeks are recommended for species discrimination [38, 39]. For example, LJ 
medium containing glycerol is used to allow the growth of MTB and inhibits the 
growth of M. bovis. When isolation of M. bovis is required, pyruvate is added to the 
culture medium instead of glycerol [40, 41]. Several improvements have been 
introduced to benefit from the sensitivity of the culture and overcome the drawback 
which is the long duration. Microscopic observation drug susceptibility (MODS) 
involves the microscopic examination of the liquid culture media (middlebrook 7H9) 
by inverted light microscope and the duration of the test is 9 days. MODS is used for 
MTB differentiation from NTM by the addition of para-benzoic acid which inhibits 
the growth of MTB only. The incorporation of antibiotics to the culture media was 
exploited to perform DST by MODS [29, 42]. Also the growth patterns differ 
according to the species so differentiation was allowed by MODS [43]. Culture-based 
DST is performed by several assays as nitrate reductase and colorimetric redox 
indicator (CRI). All these methods are based on culturing bacteria on drug-containing 
culture media. The color change indicates the ability of the resistant bacteria to grow 
in the presence of the antibiotic of interest and to perform certain reaction indicating 
the presence of resistant strains. Although the accuracy of these methods reaches 
99%, the long time to obtain the results which extends to 2 weeks limits their 
application [44-48].  
11 
 
Another type of the liquid culture is the automated liquid culture. A famous example 
is Bactec 960 MGIT (Beckton Dickson) which is enriched by oleic acid, albumin, 
dextrose and catalase to enhance the MTB bacilli growth. Drugs as polymyxin B, 
amphotericin B, nalidixic acid and trimethoprim are added to prevent contamination.  
The growth of MTB bacilli is hastened to about 7 to 10 days and the growth is 
detected by either colorimetric or fluorometric detection. Species differentiation and 
DST can also be performed. However, this method needs expensive instruments and 
trained personnel. In addition, the problem of radioactive waste products is an issue 
[3, 29]. WHO recommends performing the culture including the MODS, CRI and 
nitrate reductase in the reference laboratories only [29].  
 
1.7.7. Nucleic Acids Amplification Techniques (NAATs)  
For tuberculosis to be detected by molecular test, the bacteria should disseminate to 
the blood stream, urine, sputum and the affected organs. Molecular assays allow 
detection of MTB in clinical samples, differentiation of MTB from NTM, DST and 
performing epidemiological studies. The results are reproducible when the sample is 
smear positive and accuracy reaches more than 95%. It saves the costs of isolation of 
patients suspected to have be infected with MDR-TB or XDR-TB and cost saving is 
up to $15,000 per year [49, 50]. However, in some cases as extra pulmonary TB, 
culture is needed before performing the NAATs to increase the amount of the DNA 
[27]. 
Polymerase chain reaction (PCR) and isothermal amplification are the most common 
approaches of amplification of nucleic acid. Although the performance time extends 
to 8 hours, NAATs are much faster than culture. So these tests are the most beneficial 
in life threatening cases as meningitis MTB where smear microscopy is not suitable 
and the culture time can be too long to save the patient’s life [29]. Despite the 
development of many molecular techniques as commercial kits and in-house assays, 
LPAs (Hain Lifescience, Nehren, Germany); INNO-LipA (Fuji-Rebio Europe, 
Göteborg, Sweden); and Xpert® MTB/RIF (Cepheid, California, USA) are the only 
WHO approved molecular assays to detect MTB [24]. WHO recommends the 
molecular tests for smear positive samples when the patients had not administered any 
antibiotics (the first sample or the first smear positive sample are the suitable 
samples).
 
The sensitivity is 95% and the specificity is up to 100%. However, they are 
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recommended when the sample is smear and culture positive. While the sensitivity 
drops dramatically when the smear is negative and the culture is positive for the 
following reasons. The number of the bacteria is very few and the DNA extraction is 
faced by the strong cell wall of the bacteria. A recent study evaluated Amplicor-MTB 
(Roche, Risch-Rotkreuz, Switzerland), BD Probe (Becton Dickson) and transcription 
mediated amplification; the sensitivity was about 97% although the specificity varied 
from 71% to 96% for smear positive/culture positive samples. However, for smear 
negative/culture positive samples, the sensitivity ranged from 57% to 76%. Moreover, 
factors as the type of the sample and storage, the DNA extraction and amplification 
protocol, the visualization method of the hybridization and the presence of any 
inhibitors or contaminants will affect the accuracy [10]. So these tests are useful to 
confirm infection rapidly. Also, these assays require complex infrastructure for DNA 
extraction and test performing. The personnel should also be well-trained and work 
according to standard procedures. The risk of contamination can be overcome by the 
use of automated systems. However, the cost will be high due to the regular 
maintenance and the required reagents. Despite the presence of several assays, the 
lack of standardization limits their approval by the FDA. So till now, the gold 
standard methods for TB diagnosis are the smear microscopy confirmed by culture, 
and selective culture for DST. The diagnosis of TB patients co-infected with HIV, 
pediatric TB patients and extra pulmonary TB by sputum samples needs further 
investigation [29]. Despite the great sensitivity of molecular assays, the culture is still 
the most sensitive diagnostic tool. Most NAATs tests can’t detect TB in blood 
samples. They can’t be used to monitor the effectiveness of the therapy as the bacteria 
will be detected whether alive or dead [51]. One study revealed positive PCR results 
from patients successfully cured 2 years ago [52]. 
Sequencing of the 16s rDNA and 16S-23S internal transcribes spacer (ITS) is 
considered one of the most accurate detection methods for MTB [9, 25, 53]. The 
sequence of this region varies from 270 to 360 bp according to the species and thus 
amplification of this region followed by sequencing allows species differentiation 
[54]. The sequence of interest is compared to libraries as Genbank, the Ribosomal 
Differentiation of medical Microsystems databases and European molecular biology 
laboratory [9]. Comparison between commercially available NAATs for MTB 
detection is presented in table 4. The pipeline of NAATs for TB diagnosis is 
illustrated in table 5.  
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The variable region 16s rDNA is one of the most common sequences to target [55]. 
The gene 16s rDNA has 1500 bp. However, the first 500 bp are conserved among all 
MTB strains. So sequencing allows the exploration of unknown species [9]. Also 
IS6110 which is a non-coding insertion sequence is used frequently for direct 
detection of MTB due its repetition up to 25 times in the whole genome and was 
detected by several primers from sputum samples [22, 56]. Specific targets within 
rpoB gene are widely applied to allow detection of MTB DNA and differentiate it 
from other mycobacterium. According to the primers, the rpoB gene is used either to 
detect MTB or to detect mutations responsible for rifampicin resistance [16, 18]. 
Targets within other genes as gene of 32, 38 or 65 KD protein, recA , hsp65, dnaJ, 
sodA and 16S-23S rRNA, , groE1, or mtb-4 genes are also used to detect MTB [9, 
29]. WHO recommendations about NAATs are in table 6.  
 
1.7.7.1. Automated MTB detection assays  
COBAS® TaqMan® MTB (Roche Diagnostics) investigates 44 samples in the same 
time by the real time PCR. Liquefaction, decontamination and concentration of the 
sputum or bronchial lavage sample are a must before performing the assay. It detects 
the 16S RNA by real time PCR and the data is interpreted and stored automatically. 
The sensitivity is 96.4% for smear and culture positive specimens and drops to 76.8% 
for smear negative/culture positive. The detection limit is 18 bacilli/ml. Molecular 
Realtime MTB (Abbott, Chicago, IL, USA) is another assay that detects MTB DNA 
from NAOH-N-acetyl-L-cysteine treated sputum or bronchial lavage specimens. 
DNA extraction can also be automated. The operation time to extract and analyze 94 
samples (its capacity) extends for 7 hours. The detection limit is 17 bacilli. The 
sensitivity is 97% for smear and culture positive and 81% when the smear is negative. 
Due to the cost of the device, its wide usage is limited in the resource-limited 
countries. An automated assay that detects MTB DNA by molecular beacons is 
Fluorotype® MTB (Hain Lifescience). The DNA is amplified with the molecular 
beacons and the fluorescence is detected by specific software. Smear/ culture positive 
and smear negative/culture positive are diagnosed by sensitivity 100% and 90% 
respectively. This assay is also developed to detect MDR-TB. BD MAX™ platform 
(Becton Dickinson) which is still under development, utilizes real time PCR to detect 
MTB and to identify MDR. Its performance capacity is 24 samples in each run [24].  
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1.7.7.2. Autonomous MTB detection assays  
These assays are not automated so they require the usage of several devices, 
complicated infrastructure and trained personnel. The Anyplex (Bio-Rad 
Laboratories, Hercules, California, USA) utilizes multiplex PCR to detect MTB, 
investigate MDR-TB and XDR-TB. The primers are designed by specific software 
and sample preparation should be performed before using this assay. The second 
example is MeltPro® Drug-Resistant TB Testing Kits (Xiamen Zeesan Biotech Co. 
Ltd, Hong Kong, China) that detects point mutation of rifampicin and isoniazid by 
real time PCR. Further development are done to achieve the detection of ethambutol, 
streptomycin and fluoroquinolones resistance [24].  
 
1.7.7.3. Line probe assays 
GenoType® MTBDRplus (Hain Lifesceince) and INNO-LipA Rif.TB (Fuji-Rebio 
Europe) were the first assays approved by WHO for MTB and MDR-TB detection. 
They also allow species differentiation from NTM and investigate resistance to first 
line and second line antibiotics. Their costs are affordable for the high burden 
countries. The samples should be DNA extracted from culture and amplified to attach 
biotin and immobilized on nitrocellulose. The probes are attached to streptavidin-
bound enzyme that allows colorimetric interpretation of the results which are then 
analyzed by certain software [24]. 
 
1.7.7.4. DNA microarrays  
DNA microarrays depend on determining sequences within the 16s rRNA by 
fluorescence-labeled probes. The intensity of the fluorescence is proportional to the 
hybridization pattern and is measured by fluorescent microscopy. The results are 
available within few hours [10]. They are considered simplified form of line probe 
assays. The Autogenomics INFINITI® PLUS Analyzer platform (AutoGenomics, 
Vista, USA) is approved by FDA and can test 48 samples in 3.5 hours. The MTB 
Identification Array Kit (CapitalBio, Beijing, China) is used for MTB detection and 
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differentiation. The M. Tuberculosis Drug Resistance Detection Array Kit 
(CapitalBio) is used for MTB detection and identification of rifampicin and isoniazid 
resistance. TruArray® MDR-TB (Akonni Biosystems, Frederick, USA) is another 
microarray test that detects MTB and differentiates it from M. avium by using 
multiplex PCR to amplify the DNA and the fluorescence is detected by TRUdiagnosis 
software. VereMTB™ Detection Kit (Veredus Laboratories, Singapore) contains 500 
probes by which it identifies the MTB through targeting the IS6110 and 16S RNA, 
allows species differentiation from 8 NTM species and identifies rifampicin and 
isoniazid associated mutations [24]. 
 
1.7.7.5. Modular, cartridge-based, fully automated NAAT 
Xpert® MTB/RIF (Cepheid Inc.) is the only NAATs diagnostic assay approved by 
WHO for MTB detection [24]. Performing the test takes about 2 hours with only one 
step done manually and the reagent can be kept at room temperature for one and half 
year. The assay detects MTB and rifampicin resistance accurately especially when the 
sample is smear and culture positive [24, 29]. It has modules for sample preparation 
and semi-nested PCR of rpoB for investigation of rifampicin resistance. WHO 
recommends its use for the diagnosis of suspected MDR-TB, HIV patients and for TB 
meningitis diagnosis [24].  
 
1.7.7.6. Semi-automated NAATs 
Eiken’s Loopamp™ (Eiken Chemical Co. Ltd, Japan) MTB kit detects MTB from 
sputum samples without any pretreatment in the lysis tube by loop mediated 
amplification. Heating is used for MTB bacilli lysis [24]. It is an isothermal 
amplification assay which depends of amplification only of the target sequences when 
present. The hybridization action is investigated by gel electrophoresis to ensure the 
formation of the DNA target size. Also the double strand binds to SYBR green dye 
and the solution becomes green. However, when the target sequence is absent, the 
color of the solution remains orange. In both case, screening by ultraviolet is done 
[29]. 
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1.7.8. Detection of TB by phage-display  
The concept of these detection approaches is the use of a specific phage that infects 
only viable MTB bacilli. The number of phages is proportional to the number of 
bacterial cells. The sensitivity and specificity for smear positive are 87% and 88% and 
for smear negative/culture positive are 67% and 98%. The test needs 2-3 days to get 
results and is considered a cheap diagnostic method. The available test in the market 
is FASTPlaque TB assay (Biotic laboratories Ltd., Ipswich, UK). Another assay is 
Phage amplified biological assays (Pha B) which utilizes the mycobacteriophage D29 
detects the bacteria in only 24 hours. However, the sensitivity is only 31%. The Phage 
Tek MB assay (Organon Teknika, Durham, NC, USA) is also available in the market 
but its low sensitivity limits its use. Another assay utilizes a phage that translates the 
luciferase enzyme. When the phage infects the bacteria, it oxidizes luciferin using 
ATP. Light is generated indicating the presence of viable mycobacteria so this assay 
can also be used to test the susceptibility of the bacteria. The light intensity is 
measured by a luminometer and results are generated within 2 days [9, 29].  
 
1.7.9. Detection of TB by nanoparticles 
 
1.7.9.1. Gold nanoparticles (AuNPs) 
Spherical AuNPs has average size from 0.8 to 250 nm. The large volume: surface area 
ratio is responsible for the activity of AuNPs where the bulk gold lacks this property. 
AuNPs are widely used due to their Surface Plasmon resonance (SPR) which results 
from the collective oscillation of the electrons of the conduction band (figure 9). This 
gives the solution its red color and the absorption peak is at 520 nm for 20 nm AuNPs. 
The solution of the AuNPs turns blue upon their aggregations which red shits the 
absorption to 620 nm due to plasmon coupling of the aggregated AuNPs. This 
sensitivity is widely exploited to detect biological molecules as antigens, antibodies 
and DNA sequences [28, 57]. In addition, AuNPs are biocompatible so they are 
suitable for biological application. They can be manipulated to display several 
properties based on their particle size, surface charge, shape and inter-particle spaces 
[53]. The diversity of the AuNPs size and morphology allowed their use as scaffolds 
for the development of innovative assays platforms. The introduction of the AuNPs as 
fluorophore’s quencher was investigated 40 years ago. Fluorescence resonance energy 
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transfer (FRET) technology is defined as spectroscopic approach to measure distances 
in the range of 30-80 A° [58, 59]. AuNPs can absorb excitation energy from several 
dyes in the same time [60]. The donor particle (dye or the fluorophore) is excited by a 
certain wave length and this excitation energy is transferred to the acceptor (AuNPs) 
(figure 10). This non-radiative energy is dependent on the space between the donor 
and the acceptor [58, 60, 61]. The rate of the energy transfer is inversely proportional 
to the sixth power space between the fluorophore and the quencher [62]. Recently, the 
application of AuNPs as fluorescence quencher is useful for disease diagnosis by 
capturing a specific DNA sequence by its complementary probe. Because the 
hybridization energy is 80 kcal/mol and extremely exceed the adsorption energy of 
the fluorophore on the AuNPs surfaces (8-16 kcal/mol), the DNA probes favors the 
hybridization with their complementary targets [58, 62]. Absorption was found to be 
the prominent behavior of 40 nm AuNPs. Larger particles were found to enhance the 
fluorescence by scattering [59]. The factors affecting the non-radiative energy transfer 
between the AuNPs and the fluorophores are the morphology and the diameter of the 
AuNPs, the distance spacing the AuNPs from the fluorophore and the intersection of 
the emission of the fluorophore and the absorption of the AuNPs [63]. Several 
diseases were accurately diagnosed by FRET technology by detection of the DNA 
such as herpes simplex, Gilbert’s syndrome, parasites as malaria and toxoplasmosis, 
fungal infection as invasive aspergillosis and candidiasis [64-66]. 
 
1.7.9.1.1. AuNPs synthesis 
AuNPs synthesis is attempted by either top-down or bottom up pathway. The first 
pathway means the synthesis of AuNPs from bulk particles. The second pathway 
which is more common allows the AuNPs to grow from the corresponding chemicals 
and the size is controlled [67]. The gold salt is dissolved in a suitable solvent and 
reduced to its ground valence state by a reducing agent as the citrate which also 
stabilizes the AuNPs by prohibiting their aggregation. By controlling the reaction 
parameters which are the reducing agent type and concentration, time and 
temperature, the desired morphology and size of the AuNPs is achieved. The simple 
citrate reduction method was introduced 65 years ago [68]. The synthesis is 
performed by reducing the gold derivative (gold (III) chloride trihydrate)
 
to Au
0
 by 
sodium citrate dibasic trihydrate. The citrate can be replaced by another reducing 
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agent according the AuNPs of interest [68, 69]. 
 
When thiolated AuNPs are desired to 
by synthesized, Shiffrin method is followed [68]. The affinity between the gold and 
thiol is exploited to stabilize the gold by an alkenthiol as DDT (dodecanethiol) and the 
reduction is performed by sodium borohydride in dissolved in toluene. The thiolated 
AuNPs can be functionlized through antigen- antibody or streptavidin-biotin linkage 
with thiol groups. These particles are manipulated to allow detection of antigens, 
DNA specific sequences, peptides or carbohydrate [67-70].  
 
1.7.9.1.2. Modified AuNPs for MTB detection  
Thiol groups attached to the oligonucleotides and hence allow the binding of the 
AuNPs. If the target is present in the sample, the complementary sequences will 
anneal and AuNPs become free and aggregate in the presence of NaCl. The 
aggregation induces color change from red to blue due to the SPR of the AuNPs. Soo 
et al, developed AuNPs based assay to detect MTB by targeting IS6110 and Rv3618 
with amplicons of nested PCR and double probes specific for each target. The probes 
were linked to thiolated AuNPs and hybridization with complementary DNA 
sequence in the positive samples induced the visible color change from red to violet 
due to the shortening of the inter-particle space of the AuNPs. MTB and MTBC were 
detected with 96.6% sensitivity and 98.9% specificity, and 94.7% sensitivity and 
99.6% specificity, respectively [71]. Baptista et al, detected MTB DNA from clinical 
samples targeting the rpoB region. The detection limit was 0.75 µg [72]. Costa et al. 
developed another AuNPs based assay to detect MTBC and differentiation of MTB 
from M. bovis. Specific probes targeting the gene gyrB were allowed to hybridize 
with the amplified DNA [73]. Liandris et al. targeted 16S- 23S ITS using AuNPs 
modified probes specific for MTB. Unamplified DNA was detected with detection 
limit of 18.75 ng [74]. Das et al, developed AuNPs based biosensor by 
depositing zirconium oxide linked to MTB specific probe on gold surface. The probe 
was linked to the zirconium by exploiting the affinity between the oxygen atom of the 
phosphate backbone of ssDNA and zirconium atoms. The detection limit of the 
biosensor was 0.065 ng/µl. [75].  
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1.7.9.1.3. Unmodified AuNPs for MTB detection 
Thiolated AuNPs synthesis needs long time and is relatively cumbersome [26]. So the 
use of unmodified AuNPs saves the time, effort and cost of surface 
biofunctionlization. Hussain et al. detected MTB using 16s rDNA specific 
oligotargeter. Amplified and genomic MTB DNA were detected successfully and the 
sensitivity was 100% compared to genus and species specific semi-nested PCR [55]. 
Tsai et al, used unmodified AuNPs to detect amplified DNA by targeting IS6110. In 
case of positive samples, the probe hybridized with its target and the resulting charge 
of dsDNA was negative. The repulsion between the dsDNA and the negatively 
charged AuNPs resulted in AuNPs aggregation the color was changed from red to 
blue. If the target DNA is absent, the DNA probes would remain attracted to the 
AuNPs and prevent their aggregation and consequently, the color of the solution 
remained red. The detection limit for this assay is 2.6 nM [26]. The characteristics of 
the previous assays are compared in table 7.  
 
1.7.9.2. Detection of TB by FRET 
FRET-based detection of TB and drug resistance mutations were investigated by 
several research groups. Hwang et al. used upconversion nanoparticles (UNNPs) 
made of rare earth lanthanide elements. The assay depends on biotinylated PCR 
amplification of the IS6110 sequence of MTBC, mixing with the UCNPs conjugated 
with streptavidin (FRET donor) and addition of SYTOX orange dye that is 
intercalated in dsDNA (FRET acceptor). The decrease in green fluorescence of the 
UCNPs reports the presence and hybridization of the biotinylated PCR amplicon 
(IS6110) to the streptavidin activated UCNPs [76]. Another research group designed 
an assay that involves sandwich-form FRET for detection of the MTBC using 
cadmium telluride quantum dots (donor) and AuNPs (acceptor) that are both coupled 
to different oligonucleotides. The target region is the early secretory antigen target-6 
(ESAT-6) DNA which is conserved among all the MTBC members and is not present 
in M. bovis so allows differentiation of infection from vaccination [77]. Isoniazid 
resistance has been also investigated by FRET. Saribas et al. used real-time PCR and 
labeled probes to detect single nucleotide point mutations in the genes inhA, KatG and 
ahpC because they are known to involve the mutations responsible for isoniazid 
resistance. Two labeled probes were used: one is short probe (sensor) that hybridizes 
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at the site of mutation of interest and the longer probe (anchor) hybridizes next to it. 
When both probes become in close proximity, high fluorescence is observed. Gradual 
increase in the temperature is applied until the sensor probe is not attached anymore 
and a massive drop in the fluorescence is observed. The temperature at which the 
probe is detached is called the melting temperature. Discrimination between INH-
susceptible from resistant strains is allowed because the resistant strains have a 
different melting temperature different than the wild strains [78]. El-Haji et al. 
detected all the rifampicin associated mutations in the rpoB gene in a single assay 
using wave length shifting molecular beacons. The MTB DNA was extracted from 
sputum samples, detected by amplifying 16s rDNA region for species differentiation 
then the 81-bp region within the rpoB gene was amplified with specific primers. The 
amplicons are allowed to anneal with five beacons linked to five different 
fluorophores. Each molecular beacon is complementary for a certain mutation site. In 
case of the presence of any mutation, the molecular beacon won’t be able to hybridize 
and the fluorescence will not appear. Subsequently, only the wild type MTB will emit 
the five fluorescence colors. The molecular beacons were modified to be wave length 
shifting to allow the emission of longer wave length and better discrimination among 
the five fluorophores [79]. Qin et al, detected the MTB bacilli through fluorescent 
silica nanoparticles and SYBR- green attached to anti-tuberculous antibodies. The 
specific antibodies attach to the bacilli and the double emission of the two dyes 
indicates the presence of MTB bacilli [62]. Ekrami et al, used mouse monoclonal 
antibodies linked to silica fluorescent nanoparticles for direct detection of MTB 
bacilli from sputum samples. The anti-tuberculous antibodies are attracted to the 
surface antigens of the MTB and intense fluorescence was observed [80]. The FRET 
based assays are illustrated in table 8. 
 
 
21 
 
1.8. Thesis scope and objectives 
 
1.8.1. Development of colorimetric nano-sensor for detection of MTB DNA using 
cationic AuNPs.  
 
1.8.2. Development of AuNPs-based FRET sensor for the fluorometeric detection of 
MTB DNA.  
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Chapter 2: Materials and Methods 
2.1. Clinical bacterial strains 
 
This study was performed after getting IRB approval from the American University in 
Cairo case #2014-2015-149 and the approval of the Egyptian Ministry of Health No. 
2-2015/1. Seventy two anonymous mycobacterial samples from the Central 
Laboratories archive were used in this study (figures 11, 12). The geographic 
distribution was 24 patients from Abassia Chest Hospital, Cairo governorate, 15 
patients from Giza Chest Hospital, Giza governorate, 13 patients from Alexandria 
Governorate, 11 patients from Dakahlia Governorate, 2 patients from Suez 
Governorate, 2 patients from Helwan City, 1 patient from Matarai City, 1 patient from 
Isamlia Governorate, 1 patient from Elmenya Governorate and 1 patient from the 
Central Laboratories of Ministry of Health. 
All the samples were cultured on LJ liquid medium according to the manufacturer’s 
protocol. The culture is done from early morning sputum samples of the Egyptian 
patients from different regions all over Egypt. The patients were diagnosed to be 
infected with Mycobacterium.  None of the samples were known to be whether typical 
or atypical Mycobacterium. Reference bacterial strains include M. tuberculosis 
H37Ra (positive reference strain) and Mycobacterium smegmatis (negative reference 
strains). Four E.coli samples, Acinetobacter baumannii ATCC 17978, Pseudomonas 
aeruginosa ATCC 27853, Klebsiella pneumonia ATCC 23495 and Enterobacter 
aerogenes ATCC 13048 were the negative samples.  
2.2. DNA extraction 
Extraction was performed using QIAamp DNA mini extraction kit (Cat no. 51304, 
Qiagen, Hilden, Germany). According to the extraction protocol of gram positive 
bacteria, cell wall lysis is required prior to extraction. It is accomplished by adding the 
bacterial pellet to lysozyme enzyme 20 µg/ml (from chicken egg white, cat no. 41800, 
Norgen Biotek Corp., Thorold, Canada) dissolved in 20 mM Tris- Hcl, PH 8 (cat. no. 
10812846001, Sigma Aldrich, Missouri, USA), 2 mM EDTA (cat. no. 431788, Sigma 
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Aldrich) and 1.2 % triton (cat. no. x100, Sigma Aldrich) and incubated for 30 min at 
37 ºC. Then the extraction protocol for gram positive protocol is followed according 
to the manufacturer’s protocol. Extraction of the DNA from the gram negative was 
done according to the manufacturer’s protocol.  
2.3. Identification of the bacterial strains by PCR 
 
2.3.1. Species differentiation using Multiplex PCR 
Identification of the samples (n=72) to differentiate MTB from NTM was achieved by 
multiplex PCR. Two sets of primers targeting the rpoB region were used [30]. All the 
primers are manufactured by BioBasic, Markham, Canada. The primers and the 
amplicons size are illustrated in table 9. The reaction mixture volume was 20 μl and 
prepared by mixing 10 μl master mix (cat. no. RR310A, Takara Bio. Inc., Shiga, 
Japan), 0.75 μl of each primer type from stock concentration 10 μM, 2 μl of DNA 
samples and 5 μl of nuclease free water (NFW). The reaction conditions are 
denaturation for 3 min at 95 °C and 1 min at 97 °C, 2 cycles for 1 min at 95°C, 30 sec 
at 64 °C and 1 min at 72 °C, 2 cycles for 1 min 95 °C, 30 sec at 62 °C and 1 min at 72 
°C, 2 cycles for 1 mi at 95°C, 30 sec at 60 °C, 1 min at 72 °C, 2 cycles for 1 min at 95 
°C, 30 sec at 60 °C and 1 mi at 72 °C, 2 cycles for 1 min at 95 °C, 30 sec at 58 °C and 
1 min at 72 °C, 22 cycles for 1 min at 95 °C, 30 sec at 56 °C and 1 min at 72 °C and 1 
cycle at 72 °C for 10 min [30]. The PCR reaction was done using the thermal cycler 
(Veriti, Applied Biosystems CA, USA).  All the amplicons were examined on 1.5% 
w/v agarose gel electrophoresis stained with ethidium bromide.  
2.3.2. Amplification of 16S-23S ITS and Sequencing  
Thirteen samples were chosen randomly to be sequenced. Primers for amplification 
the region 16S-23S ITS region were chosen from literature. The primers sequences 
are: MYITSF (5’-GATTGGGACGAAGTCGTAACAAG-3’) and MYITSR (5’-
AGCCTCCCACGTCCTTCATCGGCT-3’), manufactured by BioBasic. The reaction 
mixture volume was 50 μl and prepared by mixing 25 μl master mix (cat. no. 
RR310A, Takara Bio. Inc.), 1.875 μl of both the forward and reverse primer type from 
stock solution 10 μM , 5 μl of DNA template and 12.5 μl of NFW.  The amplification 
conditions were slightly modified to initial denaturation at 95 °C for 5 min followed 
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by 35 cycles of (95 °C for 1 min, 55 °C for 30 sec and 72 °C for 1 min) , and 72 °C 
for 7 min (1 cycle)  [30].  Thirteen samples (92, 272, 187, 392, 300, 445, 348, 100, 98, 
265, 447, 394, and 114) were chosen randomly and amplified (table 10). All the 
amplicons were examined on 2% agarose for gel electrophoresis and then were 
sequenced by Macrogen (Seoul, South Korea). Then the forward and reverse 
sequences were assembled by AlignX Vector NTI 11.5 software (Life technologies, 
Carlsbad, California, USA) and finally analyzed by NCBI database. 
2.3.3. Identification of drug resistance mutations of MDR-TB by Multiplex Allele 
Specific (MAS) PCR 
The reaction mixture was 25 μl prepared as follows: 12.5 μl master mix (cat. no. 
RR310A, Takara),  1 pmol rpoB 516, 5 pmol rpoB526 , 32.5 pmol  rpoB531 , 30 
pmol RIRm , 1 pmol katG0F, 1 pmol katG5R , 2 μl of DNA template and the final 
volume is completed by NFW (tables 11, 12). The PCR conditions consisted of an 
initial denaturation at 96 °C for 3 min, 25 cycles of 95°C for 50 sec, 68°C for 40 sec, 
and 72°C for 60 sec, and a final extension at 72°C for 7 min [81]. Amplicons were 
visualized on 2% wt/vol agarose gel stained with ethidium bromide.  
2.4. AuNPs-based sensors for MTB DNA detection  
2.4.1. Cationic AuNPs-based sensor 
 
2.4.1.1. Cationic AuNPs synthesis 
Ten milliliter of 0.1% (w/v) chitosan (cat. no. 448869 Sigma Aldrich) in 1% acetic 
acid was allowed to boil, then 0.5 ml of preheated 10mM gold (III) chloride trihydrate 
(cat. no. 520918, Sigma Aldrich) added and mixed for 45 min. Characterization was 
performed by Zeta sizer (Malvern Zeta sizer 3000HSA; Malvern Instruments Ltd., 
Malvern, UK) and Scanning electron microscope (SEM) (LEO SUPRA 55; Carl Zeiss 
AG, Oberkochen, Germany). 
2.4.1.2. Amplification of MTB DNA by IS6110 primers 
PCR was performed with 5µl (50 ng) of template DNA in a reaction mixture (50 µl) 
containing 12.5 μl master mix (cat. no. RR310A, Takara), 1 µM primer from each 
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forward 5’-CCTGCGAGCGTAGGCGTCGG-3’ and reverse 5’-
CTCGTCCAGCGCCGCTTCGG-3’. The PCR started with a denaturation step (94°C 
for 3 min), followed by 35 cycles of denaturation (94°C for 1 min), annealing (68°C 
for 1 min), and extension (72°C for 1 min), and a final extension step at 72°C for 5 
min as described by Kocagoz et al. [21].  Amplicons were visualized on 1.5% wt/vol 
agarose gel stained with ethidium bromide.  
2.4.1.3. Amplification of MTB DNA by rpoB primers 
PCR was performed with 5µl (50 ng) of template DNA in a reaction mixture (50 µl) 
12.5 μl master mix (cat. no. RR310A, Takara), 1 µM primer (each) (forward 5’- 
CGTACGGTCGGCGAGCTGATCCAA -3’ and reverse 5’- 
CCACCAGTCGGCGCTTGTGGGTCAA -3’).  The PCR conditions are 95 °C for 5 
min, 30 cycles at 95°C for 30 sec, then at 72°C for 60 sec, and 72°C for 5 min as 
described before [26]. Amplicons were visualized on 1.5% wt/vol agarose gel stained 
with ethidium bromide.  
2.4.1.4. Cationic AuNPs assay 
The assay was performed by mixing 5µl of the cationic AuNPs and 20ul of amplified 
product. The mixture left for 10 minutes before detection the color change.  
2.4.1.5. Detection limit for cationic AuNPs assay 
Serial dilutions were prepared after amplifying MTB H37Ra sample. The initial DNA 
concentration was calculated by measuring the absorption at 260 and 280 nm using 
UV-Vis spectrophotometer (model 7315, Jenway, UK). DNA concentration was 
calculated using the following equation:  
DNA Concentration (µg/ml) = (A260 reading – A320 reading) × dilution factor × 50 
µg/ml 
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2.4.2. AuNPs-based FRET sensor for detection of MTB  
2.4.2.1. Anionic AuNPs synthesis 
Citrate reduction method of AuNPs was followed as previously described [68].  
Briefly, 35 ml of 0.25 mM gold (III) chloride trihydrate (cat. no. 520918, Sigma 
Aldrich)  and equal volume of 2.5 mM of sodium citrate dibasic trihydrate ( cat. no. 
C7254, Sigma Aldrich) were placed separately in two glass beakers, covered with 
aluminum foil and heated. When the gold (III) chloride trihydrate started to boil, 
sodium citrate was added and left to stir for 40 minutes till the solution color turned 
bright red. For concentration, 1.5 ml of the colloid solution was centrifuged at 14,000 
rpm for 20 minutes, and then the supernatant was dissolved in 200 µl nuclease free 
water. Characterization was performed by zeta sizer and SEM. 
 
2.4.2.2. Probe sequence 
CY-3 labeled 16s rDNA specific probe was used. The sequence of the probe was CY-
3- 5ʹ CACCACAAGACATGCATCCCG-3ʹ (BioBasic) [55].  
 
2.4.2.3. Optimization of the FRET assay  
Hybridization buffer was prepared as follows; 2.5 µl of 500 mM NaCl, 1 µl of 1µM 
CY-3 labeled probe and the final volume is completed to 10 µl by NFW. Serial 
dilutions of the AuNPs were added to the hybridization buffer. Fluorescence was 
measured to detect the optimum concentration of AuNPs for the assay; excitation and 
emission were measured at 544 and 584 nm [82], respectively (BMG Labtech 413-
3179, Ortenberg, Germany). 
 
2.4.2.4. Detection of MTB DNA using FRET assay 
Extracted DNA was added to 8ul hybridization buffer then fragmented by 5% 
sonication at 50 °C for 10 min dark (Sonorex digital 10p, Bandelin, Dusseldorf, 
Germany). Then the samples were subjected to denaturation for 3 min at 95 ºC 
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followed by annealing at 52 ºC for 45 sec by the thermal cycler. After incubation at 
room temperature for 15 min, 40 µL of AuNPs were added to each sample. Excitation 
and emission were measured at 544 and 584 nm, respectively. 
2.4.2.5. Detection limit of FRET assay 
Serial dilutions of H37Ra reference strain sample were prepared and the test was run 
as previously described. The initial DNA concentration was calculated by measuring 
the absorption at 260 and 280 nm using UV-Vis spectrophotometer. DNA 
concentration was calculated using the following equation:  
DNA Concentration (µg/ml) = (A260 reading – A320 reading) × dilution factor × 50 
µg/ml 
 
2.5. Data interpretation and statistical analysis:  
The sensitivity and specificity were calculated by the following equations:  
Sensitivity = no. of true positive / (no. of true positive + no. of false negative) ×100 
Specificity = no. of true negative / (no. of true negative + no. of false positive) × 100 
Relative fluorescence was calculated for each test by normalizing fluorescence values 
against residual fluorescence values. Unpaired Mann-Whitney U test was used for 
comparison between the two sample sets (GraphPad Prism version 4.0 for Windows, 
San Diego California, USA).  
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Chapter 3: Results 
 
3.1. Clinical bacterial strains  
Mycobacterial DNA was extracted from 72 clinical isolates of infected patients. 
Patients' gender distribution was 57 males and 15 females. All 72 Mycobacterial 
samples were characterized by multiplex PCR and FRET. Two reference strains of M. 
smegmatis and H37Ra were cultivated and used as negative and positive controls, 
respectively. Isolates of different non-mycobacterial pathogens were also recruited 
and investigated by both multiplex PCR and FRET. They involved four E.coli strains, 
Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia and 
Enterobacter aerogenes.  
 
3.2. Characterization of the bacterial strains by PCR 
 
3.2.1. Species differentiation by Multiplex PCR 
DNA extracted from all (n=72) isolates (mycobacterial and non-mycobacterial) was 
amplified via multiplex PCR, and then analyzed by gel electrophoresis.  Based on 
amplicon size reported by primer-BLAST of utilized primers, a clear 235 bp band was 
observed for H37Ra sample (positive control), while M. smegmatis (negative control) 
yielded band at 136 bp. Accordingly, 70/72 of tested samples yielded bands at 235 bp 
and were classified as MTB, while 2/72 yielded bands at 136 bp and were classified 
as NTM (figure 13). All amplicons of non-mycobacterial pathogens yielded no bands 
on gel electrophoresis. 
 
3.2.2. Amplification of 16S-23S ITS and Sequencing 
Randomly selected 13 samples out of total 72 samples (13/72) had amplicon size of 
350 bp on gel electrophoresis (figure 14). Such samples were subjected to forward 
and reverse sequencing. Clear sharp peaks with limited background noise appeared in 
the sequencing results (figures 15, 16). The forward and reverse sequences were 
assembled and analyzed by NCBI database. Twelve samples (12/13) were reported as 
MTB while only one sample (1/13) was reported as NTM (M. kansasii). The 
concordance of the sequencing with the FRET assay was 100%.   
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3.2.3. Identification of drug resistance mutation of MDR-TB by MAS- PCR 
According to the results of DST conducted on cultures, 8 samples were found to be 
rifampicin resistant, 12 samples were isoniazid resistant and 5 samples were MDR-
TB. The remaining samples were susceptible to rifampicin and isoniazid. Two NTM 
samples were reported among the isoniazid resistant samples. The samples were 
investigated by MAS PCR in which one of the primers is attached at a certain site and 
the other primers are supposed to attach in the mutation site in case of wild type only 
(figure 17). Concerning rifampicin resistance, 4 from 8 resistance mutations were 
identified: two samples had mutation in the position rpoB 516; other two had 
mutation at rpoB 531. For isoniazid resistance, only 3 samples from 12 were found to 
have the mutation in KatG 315. None of drug susceptible samples had any mutations 
when investigated by PCR (figure 18).   
3.3. AuNPs based sensors for MTB DNA detection 
 
3.3.1. AuNPs Characterization 
Characterization of anionic and cationic AuNPs was performed by SEM and Zeta 
sizer. SEM images showed spherical particles of uniform size and shape (figures 19, 
21). The average diameters of anionic and cationic AuNPs were 40 nm and 20 nm, 
respectively. Zeta sizer report revealed similar sizes' distribution and zeta potential of 
-19 mV for the anionic AuNPs (figures 20, 22).   
 
3.3.2. Cationic AuNPs-based sensor 
 
3.3.2.1. IS6110 amplification of MTB DNA 
All the 72 samples were amplified by the IS6110-specific primers according to 
previously discussed conditions. Amplicons were tested on the gel electrophoresis. 
All MTB samples have band at 123 bp (figure 23). None of the negative strains had 
bands on gel.  
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3.3.2.2.  rpoB amplification of MTB DNA 
All the 72 samples were amplified by the rpoB-specific primers according to 
previously discussed conditions. Amplicons were tested on the gel electrophoresis. 
All MTB samples had band at 235 bp (figure 24). None of the negative strains had 
bands on gel electrophoresis.  
 
3.3.2.3. Cationic AuNPs assay and Detection Limit 
The presence of amplified DNA products provided a color shift of the cationic AuNPs 
from red to blue (figure 25). Amplified MTB clinical samples showed violet-to-blue 
color with AuNPs. The red color of AuNPs persisted after adding PCR products of 
negative controls (figures 26, 27). Serial dilutions of the MTB H37Ra were prepared 
and investigated by the cationic AuNPs assay. By calculating the initial DNA 
concentration, the detection limit was found to be 5.4 ng/μl (figure 28).  
3.3.3. AuNPs-based FRET assay for MTB DNA detection 
 
3.3.3.1. Optimization of FRET assay and investigation of the clinical bacterial 
strains by FRET 
The least volume of the AuNPs to induce complete quenching of the fluorescence was 
determined by mixing gradual volumes of the AuNPs and the hybridization buffer 
containing CY-3 probe. The least volume that induced complete quenching was 40 μl 
(table 13).  
For proof-of-concept (figure 29), we first tested samples of both positive (MTB 
H37Ra) and negative (M. smegmatis) controls by multiplex PCR and FRET assay. 
Both assays succeeded to discriminate between samples. By FRET assay, the 
fluorescence yield of positive control exceeded 3-fold higher than that of negative 
control. 
FRET assay was performed on all 72 samples of mycobacterial species. Seventy 
samples (70/72) were identified to be MTB by multiplex PCR, of which, sixty nine 
samples displayed fluorescence 3-fold higher than the negative control, so exceeding 
the proposed cut off value. Only 1 sample had lower fluorescence than the cut off 
value, which means a false negative result. Two samples (2/72) were identified to be 
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NTM by multiplex PCR and FRET, both displayed fluorescence 3-fold lower than 
that of the negative control, indicating that they were NTM.  
Also, 8 negative samples which are the non-mycobacterial pathogens (four E. coli 
samples, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia, 
and Enterobacter aerogenes) were investigated by both multiplex PCR and FRET. 
Only the Enterobacter aerogenes sample had a high fluorescence exceeding the cut 
off value which means it is a false positive result. The remaining seven samples had 
lower fluorescence than the cut off value. 
To summarize, of total 72 Mycobacterium samples tested, one false negative was 
recorded; of 8 non-mycobacterial samples, one false positive was detected, translating 
to sensitivity and specificity of 98.6% and 90%, respectively. The concordance 
between the Multiplex PCR and FRET methods was 98% (figure 30).   
3.3.3.2. Detection limit by FRET 
Serial dilutions of the sample H37Ra were prepared to detect the detection limit of the 
FRET assay. The initial DNA concentration was found to be 40 ng/µl, and the 
detection limit is 10 ng/ µl. So the detection limit for the assay without prior DNA 
amplification was determined to be 10 ng/ µl (table 14).  
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Chapter 4. Discussion 
 
TB diagnosis has always been challenging, since accuracy, affordability and short 
time-to-result are critical properties of a novel assay for point-of-care. Two AuNPs-
based MTB assays developed in this study offer rapid and accurate method for MTB 
detection utilizing the minimum laboratory infrastructure. The main purpose of the 
two assays is differentiation of MTB from NTM as initial culture does not allow 
species differentiation because the colonies morphology of most mycobacteria species 
is nearly the same. So differential culture, biochemical assays or molecular assays are 
required for species differentiation [10].  
Seventy two anonymous sputum samples were collected from patients from different 
regions in Egypt. The sputum was decontaminated and cultured on LJ media in the 
Central laboratories. MTB H37Ra and M. smegmatis were the positive and negative 
control and were also cultured on LJ media in addition to 8 negative strains. The DNA 
was extracted according to the manufacturer’s protocol. DNA extraction of the 
mycobacterial species and other gram positive species was started by lysis of the rigid 
cell wall by lysozyme enzyme.  
Characterization of the clinical samples was verified by multiplex PCR to allow the 
differentiation of MTB form NTM.  Two sets of primers were used and each of them 
amplifies its target and yields amplicons of different sizes. The primers are specific 
for the region rpoB region which allowed species differentiation due to its variability 
to differentiate between mycobacterial species. The MTB samples yielded amplicons 
of size 235 bp while NTM samples yielded amplicons at 136 bp when they were 
analyzed by gel electrophoresis. Seventy samples were characterized as MTB and 
only two samples were found to be NTM.  
Further verification of the samples was done by sequencing. Random samples were 
chosen and amplified by 16S-23S ITS specific primers. All the amplicons were 350 
bp in size. This hindered differentiation of MTB from NTM sample because the 
amplicons size is nearly the same but the sequence is different. The amplicons were 
then subjected to forward and reverse primer walking sequencing followed by 
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assembling by AlignX Vector NTI 11.5 software. Then finally the resulting sequences 
from the assembly were analyzed by NCBI database. The sequencing result was 12 
MTB samples and 1 sample was NTM (M. kansasii). The concordance between the 
sequencing and the multiplex PCR was 100%. 
MAS-PCR was used to report the most common point mutations associated with 
MDR-TB, since rifampicin and isoniazid are the most powerful antibiotics against 
MTB bacilli. DST was first performed by culture in the Central laboratories. MAS-
PCR was done using 4 sets of primers to identify the point mutations. In case of wild 
type, the selected primers properly hybridized to the DNA template and amplify it. In 
case of mutation in the hybridization site, primers could not hybridize to the target 
and no amplicons were obtained. This reaction was highly specific and sensitive to 
detect single point mutation. The reported DST profiles were compared with PCR 
results. Only the main mutations were detected within the rpoB for rifampicin 
resistance and KatG for isoniazid resistance. Concerning rifampicin resistance, 4 from 
8 resistance mutations were identified: two samples had mutation in the position rpoB 
516; other two had mutation in the rpoB 531. For isoniazid resistance, only 3 samples 
from 12 were found to have the mutation in KatG 315. The resistant samples of 
undetected mutation have other mutations which are less common and were not 
investigated by their corresponding primers here.  
Two AuNPs-based sensors were developed to allow colorimetric and fluorormetric 
detection of MTB. The first sensor is the AuNPs-based sensor for colorimetric 
detection of MTB DNA. The targets were IS6110 and rpoB genes. IS6110 is a non-
encoding insertion transposal sequence and repeated up to 25 times along the MTB 
genome. It has been a common target when developing assay targeting MTB [22, 56].  
The rpoB gene is encoding for the β-subunit of RNA-polymerase of MTB and has 
been targeted by distinctive primers for either MTB detection or identification of 
rifampicin resistance associated mutations [16, 18]. The cationic AuNPs were 
synthesized using chitosan, acetic acid and gold (III) chloride trihydrate. The AuNPs 
were spherical in shape with average diameter 20 nm. The principle of the cationic 
AuNPs assay is based on the unique physicochemical properties known as SPR, 
which is responsible for characteristic color of the AuNPs. Freely dispersed AuNPs 
show a red color. When the inter-particle distance decreases, the color changes from 
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red to blue due to the red shift in the absorption spectrum to a higher wave length in 
the UV-visible spectrum. The change in the absorption results from the plasmon-
plasmon coupling of the aggregated AuNPs [69]. In case of positive samples where 
the target DNA sequence is present, the amplicons are yielded after hybridization of 
the primers. Negative-charged DNA were attracted to positively- charged AuNPs, 
leading to their aggregation, thus, color shifts from red to blue. However, in case of 
negative samples, no amplicons were obtained and AuNPs remained dispersed, thanks 
to the repulsion forces between the AuNPs which keep the intra-particle distances 
constant. Subsequently, the color remains red and no color shift occurs. The detection 
limit was determined by preparing serial dilutions of MTB H37Ra samples. Initial 
DNA concentration was calculated after measuring the samples absorption at 260 and 
280 nm and was found to be 40 ng/µl.  The last tube that displayed color change 
contained 5.4 ng/μl DNA (detection limit). 
The second sensor was AuNPs-based FRET for fluorometric detection of unamplified 
MTB DNA. Citrate reduction method was attempted for the synthesis of anionic 
AuNPs. Sodium citrate dibasic trihydrate was used to reduce the gold (III) chloride 
trihydrate. The result was citrate coated AuNPs of negative charge. The AuNPs size 
was 40 nm because this size displays the maximum absorption capacity so offers 
sufficient quenching of the fluorescence. The CY-3 dye was chosen because it has 
been used extensively to evaluate FRET phenomenon. The excitation and emission 
(544 and 584 nm) were measured according to the previous experiments [59, 61, 63]. 
The probe sequence was chosen to target 16s rDNA region because it has hyper 
variable regions that differentiate the different species of the mycobacterium genus 
and has been investigated before to allow accurate detection of MTB by AuNPs [9, 
55]. The assay was first optimized by setting the minimum AuNPs volume sufficient 
to induce the maximum fluorescence quenching. This was accessed by gradually 
increasing volumes of AuNPs added to the hybridization buffer using blank sample 
(water) instead of DNA. The adequate volume was found to be 40 µl of 40 nm AuNPs 
while larger volumes did not decrease the fluorescence significantly. The anonymous 
samples (n=72) in addition to the positive and negative controls were investigated by 
FRET sensor. When the target MTB DNA was present, the probe hybridized with the 
CY-3-16s rDNA specific probe and the more stable dsDNA structure was formed. 
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This exposes the negatively charged phosphate backbone to the outer media where the 
negatively charged AuNPs are present; resulting in repulsion and adsorption of the 
AuNPs to the DNA is prevented. Consequently, the AuNPs is spaced from CY-3 and 
fluorescence is emitted. In case of absence of the target DNA as in the M. smegmatis 
and the negative controls, the AuNPs become in close proximity to the CY-3 probe 
and quench the fluorescence for the following reasons. First, there is binding affinity 
of CY-3 fluorophore towards AuNPs (the energy of the hybridization is 80-100 
kcal/mol and the adsorption energy of the fluorophore on the AuNPs surface is 8-16 
kcal/mol ) [59]. Second, the inter-particle repulsion between the AuNPs enhances the 
adsorption of the AuNPs on the CY-3 labeled probe. Third, the non-radiative energy 
transfer between the AuNPs and the CY-3 (fluorophore) enhances the quenching of 
the fluorescence [83]. By FRET, 69 from 72 samples were found to be MTB which 
means they had relative fluorescence exceeding the estimated cut-off value that was 
three folds the negative control. Of total 72 Mycobacterium samples tested, one false 
negative was recorded; of 8 non-mycobacterial samples, one false positive was 
detected, translating to sensitivity and specificity of 98.6% and 90%, respectively. 
The concordance between the multiplex PCR and FRET methods was 98%. The 
concordance of the FRET assay, multiplex PCR, and sequencing was 100%. 
The detection limit was determined by the DNA of the reference strain MTB H37Ra. 
Serial dilutions were prepared of the sample then the hybridization buffer was 
prepared. The least concentration that displayed fluorescence higher than the relative 
cut-off value was the detection limit. The initial sample concentration was calculated 
after measuring the absorption at 260 and 280 nm and was found to be 40 ng/μl. The 
last positive fluorescence was obtained after the dilution of the sample to the quarter 
so the detection limit of the assay 10 ng/μl.  
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Chapter 5: Conclusion and Future Perspectives 
Fast and accurate diagnosis leads to better clinical and socioeconomic outcomes. Also 
reduces the chances for the spread of the disease will be precluded and the 
development of drug resistance will be averted. So the drug regimens will be shorter 
and more effective.  
The developed assays detected MTB DNA with high accuracy and sensitivity. The 
cationic AuNPs based assay detected the amplicons of the MTB DNA by just one step 
which is the addition of the AuNPs. The color change is observed visually without the 
need for any instruments. This assay can circumvent the gel electrophoresis that needs 
several preparation steps and the use of the toxic chemical ethidium bromide. The 
second assay is the AuNPs-based FRET assay. The DNA was not exposed to previous 
enzymatic digestion and amplification. The preparation of the sample needs simple 
steps after the DNA extraction. The assay is performed by just the use of the CY-3 
probe and the cost of the amplification is saved. The results are obtained shortly after 
the DNA is extracted by observing the fluorescence. The cut-off value was the 3 times 
of the base fluorescence and the positive samples are obviously discriminated from 
the negative samples. Due to the low cost and accuracy of the FRET assay, it can be 
extended for the diagnosis of TB in limited resources countries.    
Several developments can be introduced to improve the detection of TB. Non-sputum 
samples as the saliva, urine and the exhaled air should be validated for culturing and 
further investigation. DNA extraction may be improved by the use of beads to replace 
the sophisticated and expensive extraction kits. The colorimetric assay performance 
can be improved by the development of specific reader to avoid personal difference 
when judging color change and the results are analyzed spectrophotometrically. Also 
drug resistance can be investigated by the use of specific probes for the mutation sites. 
The FRET assay can be easily manipulated to detect the resistance associated 
mutations. Probes specific for the mutation points can be synthesized tagged to 
specific fluorophore. Different fluorophores with distinctive excitation and emission 
can be used to allow the diagnosis and DST in the same time.  
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6- Tables 
Table 1. First line antibiotics, mode of action and main adverse effects [2, 6, 16, 
84, 85] 
Drug name  Characteristics  Mode of action Main adverse effects  
Rifampicin  Semisynthetic 
derivative of 
rifamycin  
Inhibits the transcription 
of the β-subunit of the 
RNA polymerase  
- Allergic reaction  
- Gastrointestinal 
discomfort 
Isoniazid Prodrug which is 
activated in the 
human cell by 
bacterial catalase 
peroxidase  
Alters the synthesis of the 
mycolic acids  
- Neuropathy 
- - Allergic reaction in the 
skin 
Ethambutol Activated in 
vivo  
Inhibits the attachment of 
the mycolic acids to the 
cell wall  
- Reversible optic neuritis 
 
Streptomycin  Aminoglycoside 
antibiotic  
Inhibits bacterial proteins 
synthesis by binding to the 
30S ribosomes subunit 
which is involved in 
translation of mRNA  
- Renal toxicity 
- Ototoxicity 
 
Pyraziamide Prodrug used to 
treat tuberculosis 
activated by the 
enzyme 
pyrazinamidase  
Increases the pH of the 
cytoplasm so alters the 
normal membrane 
pressure 
- Gastrointestinal 
discomfort 
- Allergic reaction 
- Liver toxicity  
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Table 2. Genes of the common mutation(s) in the resistant MTB strains [2, 6, 16, 17, 84-87] 
Drug Genes  of common 
mutation(s) in resistant 
strains 
Normal gene role Frequency relative 
to the resistant 
strains 
Mutation site Effect of the 
associated 
mutation 
Rifampicin  RpoB 
81-bp region which is called 
Rifampicin Resistance-
Determining Region (RRDR) 
 
β-subunit of RNA polymerase  90-95% 526( H to P, D, Y) High resistance 
531 (S to L)  High resistance 
511( L to P)  Low resistance  
516 (D to V , Y) High resistance 
519 (N to Y) Low resistance 
Isoniazid  InhA Production of enoyl-acyl carrier 
protein reductase 
30% 522 (S to L) Low resistance 
inhA promoter  30% 15 Moderate resistance  
KatG  Production of catalase and 
peroxidase  
50-90% 315 (S to L) Moderate resistance  
Pyrizamide  PncA Production of the activating 
enzyme: pyrazinamidase 
60% 120 different point 
mutations  
High resistance  
Ethambutol  embB  Arabinosyl transferase 20-70% 306 Moderate resistance  
330 High resistance  
630  High resistance  
Streptomycin RpsL The ribosomal protein S12 
production  
52-59% 330 High resistance  
630  High resistance  
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Table 3. Comparison between the most applicable diagnostic approaches of TB.  
Diagnostic 
approach 
Target Advantage Disadvantage References 
Smear 
microscopy 
MTB bacilli  - Fast, cheap, simple  
 
-Low sensitivity up to 50% 
-Misdiagnose HIV co-
infected patients due to their 
low bacterial load  
[29, 30] 
Tuberculin 
skin test 
TB proteins  -Fast, cheap, simple 
-Can detect latent 
infection 
-Does not discriminate 
between infection and 
vaccination so yields false 
positive results 
-Additional assays should 
be done to confirm infection  
[12, 29, 30] 
Culture MTB bacilli  -Accurate and 
sensitive  
-Allows drug 
susceptibility testing  
-Need long time to obtain 
the results  
- Costly infrastructure 
- The personnel need prior 
training for safety  
- Does not allow species 
differentiation  
[29] 
Serological 
assays 
Anti-tuberculous 
antibodies 
-Does not need 
complicated 
infrastructure 
-Discriminate 
infection from 
vaccination 
- Sensitivity is low in HIV 
patients  
[29, 32] 
NAATs  DNA - Fast and accurate 
- Allows species 
differentiation 
- Allows DST 
- Low contamination 
risk 
-Costly infrastructure and 
consumables 
-Trained personnel are 
required 
[10, 29, 38, 
51] 
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Reaction 
type 
Assay’s name 
and fabricator  
Target Specimen 
type 
Sensitivity Ref. 
Real time 
PCR 
Cobas 
Amplicor, 
Roche  
16s rDNA 
 
Clinical 
specimens  
93% [10, 29, 38, 88-
93] 
Nested real 
time PCR 
GeneXpert 
MTB/Rif , 
Cepheid  
rpoB gene  Clinical 
specimens 
90% [29, 94-96] 
Isothermal 
transcription 
mediated 
amplification 
Amplified 
Mycobacterium 
tuberculosis 
direct, 
Genprobe 
rRNA Clinical 
specimens 
93%  
 
[10, 29, 52, 97, 
98] 
Strand 
displacement 
amplification  
Becton 
Dickson, BD 
probe tech  
IS6110 and 
16srDNA  
Clinical 
specimens 
93% 
 
[10, 29, 38, 90, 
99, 100] 
Loop 
mediate 
amplification  
LAMP , Eiken, 
Japan 
16s rRNA, 
gyrB  
Sputum 
samples 
 [29, 93, 101] 
Polymerase 
chain 
reaction  
Inno-LiPA 
Rif.TB line 
probe assay , 
Innogentics, 
Belgium 
16s-23s rRNA  Sputum and 
culture 
samples 
100%  [29, 38, 90] 
Polymerase 
chain 
reaction  
Genotype 
Mycobacterium 
and Genotype 
MTBDR plus 
assay, Hain 
lifescience, 
Germany 
23s rRNA, 
Mutations in 
rpoB, KatG 
and inhA genes  
Sputum and 
culture 
samples 
90%  [29, 38, 90] 
Table 4.  Commercially available NAATs for MTB detection  
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 Table 5. Pipeline for the development phases of TB diagnostic technologies. 
Retrieved from [24]. 
A. High complexity assays.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Late or completed 
development  
Early development 
  
On pathway to 
WHO evaluation  
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B. Moderate complexity assays.  
 
 
Molecular Detection/DST 
Xtend XDR (Cepheid) 
Alere Q (Alere) 
Enigrna ML (Enigrna 
Diagnostics) 
Q-POC (QuantuMDx) 
EOSCAPE (Wave80) 
TBDx system (KGI) 
X1 (Xagenic) 
MTB Detection (Tangen 
Biosciences) 
Genedrive MTB/RIF (Epistem) 
Truelab/Truenat MTB (Molbio) 
Xpert Ultra (Cepheid) 
  
TB LAMP (Eiken) 
Cellular Response- Detection/Latent and Latent to active progression 
T-Track TB (Lophius) 
TAM-TB (LMU/Alere) 
EAST-6/CFP-10 skin test 
(SSI) 
  QuantiFERON-
TB PLUS 
(Qiagen) 
Diaskin 
(Generium) 
Breath biomarker-Detection 
BreathLink (Menssana) 
Prototype breathanalyzer 
(Next Dimensions Tech) 
TB Breathalyser (Rapid 
Biosensor Systems) 
Aeonose (The eNose 
Company) 
    
Late or completed 
development  
Early development 
  
On pathway to 
WHO evaluation  
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C. Low complexity assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antigen, Antibody and Biomarker detection- Detection 
LAM in sputum (Standard 
Diagnostics) 
IRISA-TB (Antrum Biotec) 
  Alere Determine TB-LAM in 
urine (Alere) 
Enzymatic-Detection/DST 
β-lactamase 
reporter (Global 
BioDiagnostics) 
    
Late or completed 
development  
Early development 
  
On pathway to 
WHO evaluation  
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Table 6.  WHO recommendation:  Role of NAATs in TB diagnosis. Retrieved        
from [24].   
 
 
a: assays can be used in NTM 
b: DST can be used also for TB diagnosis 
Dx: Diagnosis 
DST: Drug Susceptibility Testing  
WGS: Whole Genome Sequencing  
Ref.: Reference laboratory, Int.: Intermediate Laboratory, Per.: Peripheral Laboratory 
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Table 7. Comparison between the main diagnostic assays for detection of MTB by AuNPs.  
 
 
 
 
 
 
AuNPs type Size of 
spherical 
AuNPs   
Sample PCR cycles Turnaround 
time 
Target Sensitivity 
and 
specificity 
Detection 
limit 
Ref.  
un modified 
AuNPs  
14 nm  DNA extracted 
from culture, 
digested by 
BamH1 enzyme 
16s rDNA : 
30 cycle, 
Semi-nested 
PCR: 25 
cycles 
1 hour 16s rDNA 100% and 
100%   
1 ng/µl for 
PCR product/ 
40 ng for 
genomic 
DNA 
[55] 
13 nm Blood samples 35 cycles 1 hour IS6110   2.6 nM [28] 
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Thiolated 
AuNPs   
13 nm Cultures 35 cycles 25-40 min gyrB locus   [73] 
        
 
         
49 sputum, 6 
bronchial 
washes, 7 
pleural effusion, 
6 urine and 5 
blood samples. 
30 cycles  
 
          
 RNA polymerase 
β_subunit   
100% 0.75 µg/µl [72] 
15-20 nm Stool samples     
 
16S-23S ITS DNA 87.5% 
and 100% 
18.75 ng/µl [74] 
13.7 nm DNA extracted 
from cultures 
prepared from 
sputum samples 
40 cycles and 
14 cycles   
1 day IS6110, Rv 3618 
DNA 
96.6% 
and 
98.9% for 
MTBC 
and 
94.7% 
and 
99.6% for 
MTB 
0.5 pmol [71] 
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Table 8. Assays developed for fluorometric detection of MTB  
Assay type Fluorophore Target Sensitivity 
and 
specificity 
Ref.  
Upconversion 
nanoparticles 
detection of MTBC 
Lanthanide 
nanoparticles and 
SYTOX orange dye 
IS6110 100% and 
100% 
[76] 
Sandwich-form 
AuNPs based FRET 
for detection of the 
MTBC 
Cadmium telluride 
quantum dots 
ESAT-6 94.2% and 
86.6% 
[77] 
Drug resistance 
detection by Real-
time PCR 
LCRed640 and 
fluorescein 
Point 
mutations in 
the genes 
inhA, KatG 
and ahpC 
76% and 
100% 
[78] 
Drug resistance 
detection by 
molecular beacons 
Texas red, fluorescein, 
tetrachlorofluorescein, 
tetramethylrhodamine, 
rhodamine 
rpoB gene 97% and 
100% 
[79] 
Detection of MTB 
bacilli 
Fluorescent silica 
nanoparticles and 
SYBR-green  
MTB bacilli      
           
[62] 
Detection of MTB 
bacilli 
Monoclonal antibodies 
with fluorescent silica 
nanoparticles  
MTB bacilli 97.1% and 
91.35% 
[80] 
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Table 9. The primers and amplicons sizes used to differentiate between MTB and 
NTM  
Forward primer  Reverse primer Amplico
n size in 
bp 
Identificatio
n 
Ref
.  
5’-
TACGGTCGGCGAGCT
GATCCAAA-3’ 
5’-
ACAGTCGGCGCTTG
TGGGTCAAC-3’ 
235 MTB [30] 
5’-
GGAGCGGATGACCAC
CCAGGACGTC-3’ 
5’-
CAGCGGGTTGTTCT
GGTCCATGAAC-3’ 
136 NTB [30]
 
 
MTB: Mycobacterium tuberculosis 
NTM: Non-tuberculous Mycobacterium 
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Table 10. Samples chosen randomly and their sequencing results 
 
 
 
 
Sequenced Samples  Sequencing result Reference 
95 NTM  Alexandria governorate 
272 MTB  Abasia chest hospital, Cairo 
governorate 
187 MTB Dakahlia governorate 
392 MTB Giza chest hospital, Giza  
governorate 
300 MTB Dakahlia governorate 
445 MTB Abasia chest hospital,  Cairo 
governorate 
348 MTB Alexandria governorate 
100 MTB Alexandria governorate 
98 MTB Alexandria governorate 
265 MTB Abasia chest hospital,  Cairo 
governorate 
447 MTB Abasia chest hospital,  Cairo 
governorate 
394 MTB Giza chest hospital,  Cairo 
governorate 
114 MTB Alexandria governorate 
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Table 11. The primers used for identification of drug resistance associated mutations [80]   
Target site of 
mutation 
Primer  Forward primer Primer  Reverse primer Amplicon size  
KatG at 315 KatG5R 5’-ATACGACCTCGATGCCGCT-3’ KatG0F 5’-
GCAGATGGGGCTGATCTACG-
3’ 
293  
rpoB at 516  rpoB516 5’-CAGCTGAGCCAATTCATGGAC-
3’ 
RIFm 5’-TTGACCCGCGCGTACAC-3’ 218 
rpoB at 526 rpoB526 5’-CTGTCGGGGTTGACCCA-3’ 
 
RIFm 5’-TTGACCCGCGCGTACAC-3’ 185 
rpoB at 531 rpoB531 5’-CACAAGCGCCGACTGTC-3’ 
 
RIFm 5’-TTGACCCGCGCGTACAC-3’ 170  
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Table 12. Amplicons size by MAS PCR. The presence of specific band size 
indicates wild type while the absence of specific band size indicated mutation and 
drug resistance.  
Mutation site  Amplicon size in bp 
KatG 315 293 
rpoB 516 218 
rpoB 526 185 
rpoB 531 170  
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Table 13. Optimization of AuNPs concentration for optimum quenching of 
fluorescence. The red arrow is pointed at the optimum AuNPs volume used in the 
FRET assay to quench the fluorescence.  
 
40 nm AuNPs dilutions Fluorescence 
Hybridization buffer (10 µl) + 40 µl NFW  59185 
Hybridization buffer + 30 µl NFW +10 µl 
AuNPs  
21908 
Hybridization buffer + 20 µl NFW +20 µl 
AuNPs 
12782 
Hybridization buffer + 10 µl NFW +30 µl 
AuNPs 
1235 
Hybridization buffer + 40 µl AuNPs 968 
Hybridization buffer + 50 µl AuNPs 955 
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Table 14. Detection limit of FRET assay investigated by H37Ra sample.  
Serial dilution of the DNA were prepared and fragmented in the hybridization buffer 
then investigated by the FRET assay. The red arrow is pointed at the least DNA 
concentration detected by FRET.  
  
Positive control  Relative fluorescence 
H37Ra 33.5 
H37Ra (1/4) 14.4 
H37Ra (1/16) 1.228 
H37Ra (1/64) 0.876 
H37Ra (1/128) 1.053 
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7- Figures 
 
 
 
Figure 1. Top causes of deaths worldwide. Deaths numbers are for 2012 (on the 
top) and for 2014 (on the bottom). The gray part is the deaths due to HIV. The TB rate 
was 1.5 million people while the HIV rate was 1.2 million. Retrieved from [3].  
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Figure 2. The incidence of TB worldwide in 2014. The number of TB patients and their geographic 
distribution are shown in different colors according to the density. Retrieved from: 
  http://www.cdc.gov/travel-static/yellowbook/2014/map_3-13.png 
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Figure 3. Tuberculosis Egypt profile. The figure is showing the incidence, 
prevalence and mortality rate of TB, MDR-TB and HIV patients with TB. Figure 
retrieved from [4]. 
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Figure 4. The cell wall of MTB.  The mycolic acids appears attached to the 
peptidoglycan in the cell wall of MTB bacilli. Retrieved from 
http://www.nature.com/nrmicro/journal/v6/n4/images/nrmicro1861-f1.jpg 
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Figure 5. The pathophysiology of MTB inside the host. After inhalation of MTB 
bacilli and in case of healthy person, some bacilli may sneak to the lower respiratory 
tract. The macrophages hurry to the site of infection and destroy the bacilli. In case of 
the failure of the macrophages to terminate the bacteria, the macrophages engulf the 
bacilli forming Ghon complex. If the host’s immunity becomes weaker, this 
granuloma may soften and the bacteria spread to the lung and other organs as the 
lymph nodes resulting in active infection. Retrieved from: 
http://www.nature.com/nrmicro/journal/v12/n4/images/nrmicro3230-f1.jpg 
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Figure 6. The MTB bacilli after ZN staining under the microscope. The bacilli 
appear as red rods under a blue background. Retrieved from 
http://commons.wikimedia.org/wiki/File:Mycobacterium_tuberculosis_Ziehl-
Neelsen_stain_02.jpg 
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Figure 7. Digital chest X-ray.  The left image is for digital chest X-ray. The right 
image is for CAD4TB analysis (specific software analyzes the images to detect any 
lung abnormalities) of the image. Both images show lung abnormalities. Retrieved 
from [24]. 
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Figure 8. Tuberculin assay. The irritation is due to reaction with the injected 
antigen.  After 48 hours, the injection site is tested. If the diameter of the injection site 
exceeded 10 mm in high risk people as infants, nurses, prisoners or HIV co-infected 
patients, this indicates TB active infection. If the diameter was 15 mm or more and 
there are no risk factors, this indicates active TB infection. Retrieved from:  
http://www.healthcentral.com/common/images/9/9231_18546_5.jpg 
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Figure 9. The Surface Plasmon resonance of AuNPs. When light with an electromagnetic 
field of a wavelength larger than AuNPs diameter hits the AuNPs, the nanoparticles 
induce a collective dipolar oscillation for the free electrons in the conduction around the 
metal nanoparticles surface. When these oscillations reach the maximum, this 
phenomenon is known as Surface Plasmon Resonance  
Retrieved from: 
http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.sv
c/ImageService/Articleimage/2015/RA/c5ra01819f/c5ra01819f-f1_hi-res.gif 
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Figure 10. The FRET energy transfer. The donor is excited by a certain wave 
length. When the donor loses this energy as non-radiative energy, it transfers to the 
acceptor if it is present in the proper distance (not less than 7 nm) that allows energy 
transfer. The non-radiative energy transfer is called resonance.  
1- Excitation of the donor by a photon from the ground state (S°) to the lowest 
excited state (S1). 
2- Energy photon release of the donor and returning to the ground energy state 
3- Energy transfer from the donor to the acceptor and excitation of the acceptor 
4- Release of photon from the acceptor 
5- Energy release of the acceptor to the ground energy state 
Retrieved from: 
http://chemwiki.ucdavis.edu/Theoretical_Chemistry/Fundamentals/Fluorescence_Res
onance_Energy_Transfer 
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Figure 11. Geographic distribution of the samples collected in Egypt. The 
anonymous samples were obtained from patients of different geographic locations.  
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Figure 12. Drug sensitivity results as obtained by culture. The sensitivity of the 
first line antibiotics was investigated by culture in the Central Laboratories   
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Figure 13. Gel electrophoresis of multiplex PCR of mycobacterial samples. The 
amplicons were investigated on 1.5% agarose gel stained with ethidium bromide and 
visualized by UV. Samples 446, 277, 272, 448, 121, 275, 450, 443 and 119 were 
proven to be MTB because the bands appeared at 235 bp. R: MTB H37Ra is the 
reference strain and had a band at 235 bp.  S: M. Smegmatis which is NTM had a band 
at 136 bp.  E: is E.coli sample did not have any band and c: control is just a blank by 
water instead of the sample.  
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Figure 14. PCR  amplification of randomly chosen samples by 16S-23S ITS primers. The 
randomly chosen samples were amplified and the amplicons were analyzed by 1.5% agarose 
gel stained with ethidium bromide. All the bands appeared at 350 which only verify the 
amplification but do not allow differentiation of the different species. The amplicons were 
then sequenced.  
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Figure 15. Sequencing peaks of sample 300. After the samples were amplified by 
16S-23S ITS primers, the amplicons were purified and subjected to forward and 
reverse primer walking sequencing by Macrogen, South Korea.  
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Figure 16. NCBI BLAST analysis of sample 300. After assembling of the forward and 
reverse sequences, the NCBI analysis was done.  
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Figure 17. Primers sites for amplification of MTB mutation sites. Only wild type 
allows amplification and mutated types do not yield any amplicons. Figure retrieved 
from [81].   
 
218 bp 
185 bp 
170 bp 
293 bp 
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Figure 18. Gel electrophoresis of MAS PCR of Mycobacterial samples. Sample 
186 was proven to be rifampicin resistant by culture, by PCR, the band at 170 bp was 
absent which means that rifampicin resistance is due to mutation in rpoB gene at 531 
bp. Sample 267 was Isoniazid resistant by culture. However, the resistance was 
probably due to other mutation rather than KatG gene.   
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Figure 19. Anionic AuNPs characterization by SEM. After preparation of the 
AuNPs without concentration, 10 µl are allowed to dry on aluminum foil covering a 
glass slide. After complete dryness of the AuNPs, investigation is performed by SEM. 
The particles are spherical, of nearly uniform size and the average diameter is 40 nm.  
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Figure 20. Anionic AuNPs characterization by zeta sizer. After preparing the 
AuNPs without concentration, 100 µl of the AuNPs are added to 1900 µl NFW and 
then fill the cuvette from this dilution. The peak is at 40 nm.  
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Figure 21. SEM imaging of cationic AuNPs. After preparation of the AuNPs without 
concentration, 10 µl are allowed to dry on aluminum foil covering a glass slide. After 
complete dryness of the AuNPs, investigation is performed by SEM. The particles are of 
uniform shape and diameter. The average diameter is 20 nm.  
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Figure 22. Zeta sizer characterization of cationic AuNPs. After preparing AuNPs 
without concentration, 100 µl of the AuNPs are added to 1900 µl NFW and then fill 
the cuvette from this dilution. The peak is at 20 nm.  
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Figure 23. Gel electrophoresis of IS6110 amplification of bacterial strains. 
Samples 335, 331, 358, 100, 98, 94, 300, 15, 17 and 12 are Mycobacterium 
tuberculosis samples and yielded bands at 123 bp , E. coli  (E) sample and  M. 
smegmatis (S) sample did not had any bands because they lack the amplified 
sequence.
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Figure 24. Gel electrophoresis of rpoB amplification of bacterial strains: samples 
335, 331, 358, 100, 98, 94, 300, 15, 17, 12, 4, 5 and 12 are Mycobacterium 
tuberculosis samples and yielded bands at 235 bp. M. smegmatis (S) did not yield any 
band.
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Figure 25. Diagram for Cationic AuNPs assay. In the case of positive samples, the 
presence of the target DNA sequence resulted in formation of amplified DNA 
product. The negative DNA charge will attract the positively charged AuNPs leading 
to their aggregation and thus the appearance of the blue color. However, in case of 
negative samples, no PCR product formed and the AuNPs remain dispersed.  The 
repulsion forces between the AuNPs keep the intra-particles distances constant, 
subsequently, the colloidal color remains red. Azzazy ©. 
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Figure 26. Cationic AuNPs assay of rpoB amplicons of MTB DNA samples. 335, 
358, 331, 100 and 98. S: M. smegmatis sample. The MTB samples were amplified by 
the rpoB primers then cationic AuNPs were added to the amplicons. The attraction 
between the negatively charged amplicons and the positively charged AuNPs induced 
the color from red to violet due to the AuNPs aggregation. The M. smegmatis was not 
amplified because it lacks the complementary sequences for the primers hybridization 
so the AuNPs remained dispersed.  
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Figure 27. Cationic AuNPs assay of IS6110 amplicons of MTB DNA samples: 2, 
4, 5, 6, 10, 11, 12, NI (M. smegmatis sample, pointed by red arrow), 17, 13, 15, 16, 
14, 20, N2 (E.coli sample, pointed by red arrow). The numbered samples are MTB 
samples and thus the tubes turned blue.  The MTB samples were amplified by the 
IS6110 primers then cationic AuNPs were added to the amplicons. The attraction 
between the negatively charged amplicons and the positively charged AuNPs induced 
the color from red to violet due to the AuNPs aggregation. The M. smegmatis was not 
amplified because it lacks the complementary sequences for the primers hybridization 
so the AuNPs remained dispersed.  
  
 
 
 
 
 
81 
 
 
 
 
Figure 28. Detection limit by Cationic AuNPs assay of IS6110 amplicons. Serial 
dilutions were prepared and investigated. The initial DNA concentration was 
calculated after measuring absorption at 260 and 280 nm. The detection limit was the 
least amount of DNA induced color change and was found to be 5.4 ng/µl.  
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Figure 29. Diagram for FRET assay. In presence of the target in case of MTB 
DNA, the probe hybridizes with the CY3-16s rDNA specific probe; the more stable 
dsDNA structure is formed. This exposes the negatively charged phosphate backbone 
to the outer media where the negatively charged AuNPs are present; resulting in 
repulsion and adsorption of the AuNPs to the DNA is prevented. Consequently, the 
gold nanoparticle is spaced from CY-3 and fluorescence is emitted.  In absence of the 
target as in the M. smegmatis and the negative controls, the AuNPs become in close 
proximity to the CY-3 probe. Azzazy ©. 
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Figure 30. FRET results by CY-3 16s rDNA specific probe. The MTB samples were 
above the cut-off value which is 3 folds the negative control value. The M. smegmatis and the 
negative samples were under the cut-off value.  
 
 
 
 
 
 
 
 
 
 
Cut-off value  
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